Why Is PTC Therapeutics Stock Trading Higher Today?

Benzinga
2025.07.29 19:02
portai
I'm PortAI, I can summarize articles.

Sephience is approved for sepiapterin-responsive PKU in patients 1 month and older. Wholesale cost is $40,000 a month; U.S. launch starts in August, targeting 1,200 prescribers. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.